Latest Content

In this inaugural episode, experts discuss the limitations of current diagnosis-based frameworks in suicide research, emphasizing the need for more targeted interventions.

Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.

Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.

Experts urge early bipolar disorder treatment, highlighting lithium’s underuse despite neuroprotective, antisuicidal benefits and evidence that delays worsen outcomes and responsiveness.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Discover an objective suicide risk assessment for patients denying ideation, using Suicide Crisis Syndrome and staged warning signs to guide earlier intervention.

New DOE RISE rule cuts federal loan limits for graduate nursing, PAs, and social work—threatening workforce diversity and care access.

FDA issues CRL for CTx-1301 in ADHD.

Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.